Xiamen Amoytop Biotech Stock Working Capital
| 688278 Stock | 76.15 2.00 2.56% |
Xiamen Amoytop Biotech fundamentals help investors to digest information that contributes to Xiamen Amoytop's financial success or failures. It also enables traders to predict the movement of Xiamen Stock. The fundamental analysis module provides a way to measure Xiamen Amoytop's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Xiamen Amoytop stock.
As of March 16, 2025, Net Working Capital is expected to decline to about 574.3 M. The current year's Change In Working Capital is expected to grow to about (103.5 M). Xiamen | Working Capital |
Xiamen Amoytop Biotech Company Working Capital Analysis
Xiamen Amoytop's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Xiamen Amoytop Working Capital | 936.53 M |
Most of Xiamen Amoytop's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Xiamen Amoytop Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
Xiamen Net Invested Capital
Net Invested Capital |
|
In accordance with the company's disclosures, Xiamen Amoytop Biotech has a Working Capital of 936.53 M. This is 120.02% higher than that of the Biotechnology sector and 73.88% higher than that of the Health Care industry. The working capital for all China stocks is 36.64% higher than that of the company.
Xiamen Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Xiamen Amoytop's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Xiamen Amoytop could also be used in its relative valuation, which is a method of valuing Xiamen Amoytop by comparing valuation metrics of similar companies.Xiamen Amoytop is currently under evaluation in working capital category among its peers.
Xiamen Fundamentals
| Return On Equity | 0.4 | ||||
| Return On Asset | 0.22 | ||||
| Profit Margin | 0.29 % | ||||
| Operating Margin | 0.35 % | ||||
| Current Valuation | 30.4 B | ||||
| Shares Outstanding | 406.8 M | ||||
| Shares Owned By Insiders | 67.08 % | ||||
| Shares Owned By Institutions | 16.59 % | ||||
| Price To Book | 13.68 X | ||||
| Price To Sales | 11.00 X | ||||
| Revenue | 2.1 B | ||||
| Gross Profit | 2.82 B | ||||
| EBITDA | 1.02 B | ||||
| Net Income | 555.45 M | ||||
| Total Debt | 4.16 M | ||||
| Book Value Per Share | 5.57 X | ||||
| Cash Flow From Operations | 512.1 M | ||||
| Earnings Per Share | 1.82 X | ||||
| Target Price | 72.51 | ||||
| Beta | 0.39 | ||||
| Market Capitalization | 30.98 B | ||||
| Total Asset | 2.36 B | ||||
| Retained Earnings | 955.01 M | ||||
| Working Capital | 936.53 M | ||||
| Net Asset | 2.36 B | ||||
| Last Dividend Paid | 0.41 |
About Xiamen Amoytop Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Xiamen Amoytop Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Xiamen Amoytop using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Xiamen Amoytop Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Xiamen Stock
Xiamen Amoytop financial ratios help investors to determine whether Xiamen Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Xiamen with respect to the benefits of owning Xiamen Amoytop security.